Intel stock spikes after report of possible US government stake
Investing.com - D. Boral (OTC:BOALY) Capital raised its price target on CervoMed (NASDAQ:CRVO) to $15.00 from $10.00 on Monday, while maintaining a Buy rating on the stock. Currently trading at $9.85, the company has a market capitalization of $86 million, with analyst targets ranging from $10 to $27.
The firm increased its probability of clinical success factor for neflamapimod in dementia with Lewy bodies from 10% to 15%, citing a strengthened translational link between drug exposure and clinical benefit demonstrated with the New Capsule formulation.
D. Boral Capital noted that data regarding the updated pharmacokinetic and pharmacodynamic profile addressed a key source of prior uncertainty, confirming that suboptimal plasma exposure from earlier capsules likely limited efficacy.
The research firm highlighted the identification of a robust biomarker threshold (ptau181
CervoMed’s safety profile remains favorable according to the firm, with encouraging signals such as reduced fall incidence in select subgroups further supporting confidence in advancing the program. The stock has shown remarkable momentum, gaining over 360% in the past six months. InvestingPro subscribers can access 8 additional key tips about CRVO’s investment potential.
In other recent news, CervoMed has reported promising results from its RewinD-LB trial, showing that its experimental drug, neflamapimod, significantly slowed the progression of dementia with Lewy bodies. The company announced that patients treated with neflamapimod demonstrated a 54% reduction in the risk of clinically significant worsening over 32 weeks, with the risk reduction improving to 64% among patients with minimal Alzheimer’s disease co-pathology. This positive data has led Canaccord Genuity to raise its price target for CervoMed to $27, maintaining a Buy rating, due to improved approval odds for the drug. Chardan Capital Markets also maintained its Buy rating with a $15 target, noting CervoMed’s strong financial position, which includes $35.2 million in cash and securities, expected to support operations into mid-2026. The company plans to present further data from the 32-week extension phase of its Phase 2b study at an upcoming conference. These developments come after CervoMed identified that previous negative trial results were due to expired capsules, not the drug’s efficacy. The recent findings have been shared at the Alzheimer’s Association International Congress 2025, highlighting significant progress in the treatment of dementia with Lewy bodies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.